Venetoclax combined with low-dose cytarabine or azacitidine also achieved a higher molecular response rate in leukemia patients with or without IDH2-R140, FLT3-ITD, or DNMT3A mutations.[10]IDH1/2-mutated patients treated with venetoclax combined with azacitidine had a high response rate, prolonged remission, and significantly improved survival.[11] In our patient, early suspicion of APL with PML::RARA based on morphology and immunophenotyping prompted immediate initiation of ATRA therapy for a total of 22 days. The gene discussed is DNMT3A; the disease is acute promyelocytic leukemia.